ArticleCancers2025

Real-World Evidence of Long-Term Disease Control in HER2-Positive Metastatic Breast Cancer Patients Treated with a First-Line Combination of Trastuzumab and/or Pertuzumab Plus Chemotherapy.

Loïc Chaigneau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.